Spermine synthase (SMS) serves as a prognostic biomarker in head and neck squamous cell carcinoma: a bioinformatics analysis

被引:4
|
作者
Pan, Xiaoyu [1 ,2 ]
Xue, Lijun [3 ]
Sun, Yihan [1 ,2 ,4 ,5 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 2, Dept Neck Surg, Wenzhou, Peoples R China
[2] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China
[3] Wenzhou Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Wenzhou, Peoples R China
[4] Wenzhou Med Univ, Affiliated Hosp 2, Dept Neck Surg, Wenzhou 32500, Peoples R China
[5] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 32500, Peoples R China
关键词
Head and neck squamous cell carcinoma (HNSC); prognosis; spermine synthase (SMS); bioinformatics analysis; biomarker; CANCER; RNA;
D O I
10.21037/atm-22-5014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Head and neck squamous cell carcinoma (HNSC) is an aggressive type of cancer that lacks early detection, and therefore, has a low 5-year survival rate. The spermine synthase (SMS) gene has been shown to be associated with Snyder-Robinson syndrome and poor prognosis of multiple cancers; however, its regulatory role in HNSC has never been investigated. Therefore, we explored the potential predictive value of SMS in HNSC.Methods: We explored the association between SMS expression and clinicopathological parameters of HNSC patients by using data from The Cancer Genome Atlas datasets (TCGA). The prognostic value of SMS was evaluated using the Kaplan-Meier plotter, Gene Expression Profiling Interactive Analysis (GEPIA) 2 and univariate and multivariate Cox regression analyses. We further used gene set enrichment analysis (GESA) to investigate the potential roles of SMS in HNSC prognosis and Tumor Immunity Estimation Resource 2.0 (TIMER2.0) to analyze the correlation between immune cell infiltration and SMS expression. Finally, starBase was used to screen out prognosis-associated non-coding RNA genes to constructed the competing endogenous RNA (ceRNA) network. Co-expression and survival analyses were used to identify the ceRNA network's effect on HNSC prognosis.Results: We found that SMS expression was increased in HNSC compared with normal tissues (P<0.05). In addition, SMS expression was associated with tumor grade (P=0.006), N stage (P=0.001), and prognosis. Survival analysis revealed that high expression of SMS showed worse overall survival (OS) (HR =1.4, P=0.01) and worse disease-free survival (DFS) (HR =1.5, P=0.014). Multivariate Cox analysis further supported the prognostic value of SMS in HNSC (HR =1.006636, P=0.0056). GESA showed that SMS was involved in metabolism-and immune-related pathways. The immune infiltration analyses results showed a decrease in the landscape of immune cell infiltration with high SMS expression and SMS deletion in HNSC. Finally, a ceRNA network (SMS/hsa-miR-23b-3p/KTN1-AS1 and VPS9D1-AS axis) was constructed based on the co expression and survival analyses in HNSC.Conclusions: Our findings first revealed that SMS functioned as a potential prognostic biomarker and provide insights into the molecular mechanisms of its function in HNSC. The use of SMS may be powerful for determining worse prognosis HNSC patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Identification and analysis of genes associated with head and neck squamous cell carcinoma by integrated bioinformatics methods
    Jin, Yu
    Yang, Ya
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2019, 7 (08):
  • [42] Identification of novel therapeutic targets for head and neck squamous cell carcinoma through bioinformatics analysis
    Jeong, Eun-jeong
    Kim, Eunjeong
    Kim, Yeon Soo
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [43] XPA-A Biomarker With Potential Prognostic Value in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma
    Prochnow, S.
    Muenscher, A.
    Knecht, R.
    Wilczak, W.
    Clauditz, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 939 - 939
  • [44] BASP1 is a prognostic biomarker associated with immunotherapeutic response in head and neck squamous cell carcinoma
    Pan, Xue
    Xu, Xun
    Wang, Lixuan
    Zhang, Siyuan
    Chen, Yingyao
    Yang, Rongchun
    Chen, Xijuan
    Cheng, Bin
    Xia, Juan
    Ren, Xianyue
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [45] FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma
    Liang, Huazhen
    Zhang, Chunning
    Li, Chaoming
    Li, Changguo
    Wang, Yanli
    Lin, Huaming
    BIOSCIENCE REPORTS, 2021, 41 (07)
  • [46] HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma
    Chen, Yan
    Yang, Jianfeng
    Jin, Hangbin
    Wen, Weiwei
    Xu, Ying
    Zhang, Xiaofeng
    Wang, Yu
    PEERJ, 2023, 11
  • [47] Downregulation of serum miR-329 is an unfavorable prognostic biomarker in head and neck squamous cell carcinoma
    Li, Dongying
    Tao, Zezhang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (03): : 3157 - 3162
  • [48] Dickkopf-1 is a Prognostic Biomarker of Head and Neck Squamous Cell Carcinoma that Correlates with Immune Infiltrates
    Zhao, C.
    Jin, F.
    Li, Y.
    Liu, L.
    He, Q.
    Feng, J.
    Zeng, Z.
    Chen, Y.
    Li, Y.
    Xu, X.
    Zhu, S.
    Ye, Y.
    Zhou, D. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E281 - E281
  • [49] FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma
    Koole, Koos
    Brunen, Diede
    van Kempen, Pauline M. W.
    Noorlag, Rob
    de Bree, Remco
    Lieftink, Cor
    van Es, Robert J. J.
    Bernards, Rene
    Willems, Stefan M.
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3884 - 3893
  • [50] Dysregulated cholinergic network as a novel biomarker of poor prognostic in patients with head and neck squamous cell carcinoma
    Ana Cristina Castillo-González
    Susana Nieto-Cerón
    Juan Pablo Pelegrín-Hernández
    María Fernanda Montenegro
    José Antonio Noguera
    María Fuensanta López-Moreno
    José Neptuno Rodríguez-López
    Cecilio J Vidal
    Diego Hellín-Meseguer
    Juan Cabezas-Herrera
    BMC Cancer, 15